Eton Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway.
Eton is focused on bringing products to patients through the FDA’s 505(b)(2) regulatory pathway. Its pipeline includes nearly a dozen products in various stages of development across a variety of dosage forms. Eton’s pipeline is focused on innovative 505(b)(2) products and marketed unapproved drugs.
Eton Pharmaceuticals Appoints Paul V. Maier to its Board of Directors
Sep 14, 2017
Eton Pharma Appoints Dr. Norbert Riedel to its Board of Directors
September 7, 2017
©2017 by Eton Pharmaceuticals
21925 W. Field Pkwy, Suite 235
Deer Park, IL 60010